Vasoactive Agents for the Management of Acute Variceal Bleeding: A Systematic Review and Meta-analysis
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES(2021)
摘要
Background & Aims: Vasoactive agents with endoscopic therapy are used to treat acute variceal bleeding (AVB). There are two main groups of vasoactive agents: terlipressin and vasopressin (T-V), and octreotide and somatostatin (O-S). However, the benefit/harm balance is unclear. Our aim was to assess the efficacy and safety of T-V versus O-S for the management of AVB. Methods: We performed a systematic search for randomized controlled trials (RCTs) in PubMed, Scopus, and CENTRAL. Our main outcomes were mortality and adverse events. Secondary outcomes were bleeding control, rebleeding, blood transfusion, hospital stay. We evaluated the certainty of evidence using GRADE methodology. Results: We included 21 RCTs. The risk of mortality (RR: 1.01; 95%CI: 0.83-1.22), bleeding control (RR: 0.96; 95%CI: 0.91-1.02; I-2=53%), early rebleeding (RR: 0.91; 95%CI: 0.66-1.24: I-2=0%), late rebleeding (RR: 0.94; 95 CI: 0.56-1.60; I-2=0%), blood transfusion (MD: 0.04; 95%CI: -0.31-0.39; I-2=68%) and hospital stay (MD: -1.06; 95%CI: -2.80-0.69; I-2=0%) were similar between T-V and O-S groups. Only 15 studies reported adverse events, which were significantly higher in the T-V compared to the O-S group (RR 2.39; 95%CI: 1.58-3.63; I-2=57%). The certainty of evidence was moderate for the main outcomes, and low or very low for others. Conclusions: In cirrhotic patients with AVB, those treated with T-V had similar mortality risk compared to O-S. However, the use of T-V showed an increased risk of adverse events compared to O-S.
更多查看译文
关键词
liver cirrhosis,octreotide,somatostatin,terlipressin,vasopressin
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要